The pathogenic human retrovirus Human Immunodeficiency Virus 1 (HIV-1) gives rise to a long-lasting disease course which is marked by a number of distinct phases. In particular, these include an initial asymptomatic period that may last for several years but that eventually leads, in most cases, to progressively more severe immune dysfunction. The observed interaction between this human retroviral pathogen and the infected host shares some similarities with the chronic disease states induced by related animal retroviruses of the lentivirus sub-group. It is presumably no coincidence that HIV-1 also shares with these animal lentiviruses an unexpectedly complex genetic make-up. Thus, HIV-1 has been shown to encode a number of apparently non-structural proteins of which at least two termed tat and rev (formerly art/trs) have been shown to be essential for viral replication in vitro. This grant proposal addresses itself to the mechanism of action of the second of these two proteins, rev. In particular, we will attempt to define functional domains within the rev protein by a comprehensive mutational analysis approach. We will define sequences within the HIV-1 genome which are required in cis for phenotypic response to the rev gene product. We will then use this information to define and characterize proteins that are involved in mediating functional recognition of this sequence. Finally, we will attempt to completely dissect the effect of rev on viral mRNA transport and stability and on the differential processing of viral transcripts. This comprehensive approach to the understanding of rev function should lead to significant insights into the regulation of HIV-1 gene expression. Such an understanding is potentially key to the relational design of agents intended to intervene in the pathogenic course of human HIV-1 infection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29AI028233-03
Application #
3455191
Study Section
Special Emphasis Panel (ARR (V1))
Project Start
1989-04-01
Project End
1994-03-31
Budget Start
1991-04-01
Budget End
1992-03-31
Support Year
3
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Duke University
Department
Type
Schools of Medicine
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Madore, S J; Tiley, L S; Malim, M H et al. (1994) Sequence requirements for Rev multimerization in vivo. Virology 202:186-94
Fridell, R A; Partin, K M; Carpenter, S et al. (1993) Identification of the activation domain of equine infectious anemia virus rev. J Virol 67:7317-23
Malim, M H; Cullen, B R (1993) Rev and the fate of pre-mRNA in the nucleus: implications for the regulation of RNA processing in eukaryotes. Mol Cell Biol 13:6180-9
Tiley, L S; Madore, S J; Malim, M H et al. (1992) The VP16 transcription activation domain is functional when targeted to a promoter-proximal RNA sequence. Genes Dev 6:2077-87
Cullen, B R; Garrett, E D (1992) A comparison of regulatory features in primate lentiviruses. AIDS Res Hum Retroviruses 8:387-93
Cullen, B R (1992) Mechanism of action of regulatory proteins encoded by complex retroviruses. Microbiol Rev 56:375-94
Garrett, E D; Cullen, B R (1992) Comparative analysis of Rev function in human immunodeficiency virus types 1 and 2. J Virol 66:4288-94
Tiley, L S; Malim, M H; Tewary, H K et al. (1992) Identification of a high-affinity RNA-binding site for the human immunodeficiency virus type 1 Rev protein. Proc Natl Acad Sci U S A 89:758-62
Hwang, S S; Boyle, T J; Lyerly, H K et al. (1992) Identification of envelope V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1. Science 257:535-7
Keller, A; Garrett, E D; Cullen, B R (1992) The Bel-1 protein of human foamy virus activates human immunodeficiency virus type 1 gene expression via a novel DNA target site. J Virol 66:3946-9

Showing the most recent 10 out of 13 publications